INT17548

From wiki-pain
Revision as of 06:29, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1990
Last Reported 2011
Negated 0
Speculated 0
Reported most in Abstract
Documents 30
Total Number 33
Disease Relevance 24.69
Pain Relevance 3.93

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Serpine1) extracellular region (Serpine1)
Anatomy Link Frequency
plasma 4
platelet 2
coronary artery 1
blood 1
endothelial cells 1
Serpine1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
nMDA receptor 3 99.12 Very High Very High Very High
antagonist 8 98.92 Very High Very High Very High
cytokine 43 96.56 Very High Very High Very High
Pain 17 96.40 Very High Very High Very High
Inflammation 124 95.72 Very High Very High Very High
Angina 18 94.00 High High
fibrosis 95 92.40 High High
b2 receptor 4 86.76 High High
Inflammatory response 13 86.40 High High
bradykinin 10 85.96 High High
Disease Link Frequency Relevance Heat
Increased Venous Pressure Under Development 21 99.78 Very High Very High Very High
Diabetes Mellitus 303 99.40 Very High Very High Very High
Sepsis 46 99.32 Very High Very High Very High
Endotoxemia 5 98.74 Very High Very High Very High
Adult Respiratory Distress Syndrome 36 98.64 Very High Very High Very High
Metabolic Syndrome 16 98.44 Very High Very High Very High
Coronary Vasospasm 10 98.16 Very High Very High Very High
Myocardial Infarction 144 98.08 Very High Very High Very High
Insulin Resistance 27 97.82 Very High Very High Very High
Disorder Of Lipid Metabolism 41 97.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We also showed that inhibition of the tissue type plasminogen activator (tPA-stop/PAI-1) significantly interfered with the activity-induced increase in perforated synapses.
Negative_regulation (inhibition) of PAI-1 in synapses
1) Confidence 0.57 Published 1999 Journal Eur. J. Neurosci. Section Abstract Doc Link 10594650 Disease Relevance 0 Pain Relevance 0.35
Therapeutic interventions that may alter this evolution by reducing concentrations of PAI-1 or correct metabolic derangements that promote it are being studied.
Negative_regulation (reducing) of PAI-1
2) Confidence 0.56 Published 2002 Journal Am. J. Med. Section Abstract Doc Link 12431758 Disease Relevance 1.16 Pain Relevance 0.08
In healthy women taking oral contraception, there is an increase of fibrinolytic proteins: elevation of plasmin, factors VII, X, IX and a decrease of plasminogen activator inhibitor (PAI) [12-14].
Negative_regulation (decrease) of PAI
3) Confidence 0.41 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2918592 Disease Relevance 0.30 Pain Relevance 0.20
Serpine1 is highly up-regulated at day 3, but decreases after that.
Negative_regulation (decreases) of Serpine1
4) Confidence 0.38 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2688838 Disease Relevance 0.85 Pain Relevance 0.24
This hormone-associated reduction of PAI-1 was observed despite increased triglycerides, a known inducer of PAI-1 levels.
Negative_regulation (reduction) of PAI-1
5) Confidence 0.33 Published 1996 Journal Am. J. Cardiol. Section Abstract Doc Link 8888658 Disease Relevance 0 Pain Relevance 0
CONCLUSIONS: It is well known that PAI activity determines the whole fibrinolytic capacity and oral administration of nicorandil decreased PAI activity in patients with coronary artery disease.
Negative_regulation (decreased) of PAI in coronary artery
6) Confidence 0.29 Published 2004 Journal Circ. J. Section Body Doc Link 14993778 Disease Relevance 0.06 Pain Relevance 0
Hormone replacement therapy in postmenopausal women has been shown to enhance fibrinolytic capacity by lowering plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator inhibitor (tPA) antigen values.
Negative_regulation (lowering) of PAI-1
7) Confidence 0.24 Published 1996 Journal Am. J. Cardiol. Section Abstract Doc Link 8888658 Disease Relevance 0.27 Pain Relevance 0.09
In the AMI group, both the plasma and platelet PAI-1 concentrations were greater on day 1, but the plasma PAI-1 rapidly decreased by day 5 and remained low on day 28 compared with day 1.
Negative_regulation (decreased) of PAI-1 in plasma associated with myocardial infarction
8) Confidence 0.23 Published 2000 Journal Jpn. Circ. J. Section Abstract Doc Link 10952148 Disease Relevance 1.57 Pain Relevance 0.12
The platelet PAI-1 concentration gradually decreased by day 5 and was further decreased by day 28.
Negative_regulation (decreased) of PAI-1 in platelet
9) Confidence 0.17 Published 2000 Journal Jpn. Circ. J. Section Abstract Doc Link 10952148 Disease Relevance 1.41 Pain Relevance 0.12
The platelet PAI-1 concentration gradually decreased by day 5 and was further decreased by day 28.
Negative_regulation (decreased) of PAI-1 in platelet
10) Confidence 0.17 Published 2000 Journal Jpn. Circ. J. Section Abstract Doc Link 10952148 Disease Relevance 1.42 Pain Relevance 0.12
As shown in Figure 3(a), representing the protein level results, administration of danshen and tanshinone IIA increased the level of FGF-2, MMP 9, and uPA but decreased the level of PAI-1.
Negative_regulation (decreased) of PAI-1
11) Confidence 0.14 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2997511 Disease Relevance 0.07 Pain Relevance 0
In our results, danshen and tanshinone IIA-treated Schwann cells demonstrated dose-dependently increased growth rate (Figures 2(a)–2(c)), protein levels of FGF-2, its downstream JNK, ERK and even P38 signaling, and uPA activity with inhibited PAI-1 and the activation of cyclin D, E and B (Figures 3(a)-3(b) and Figures 4(a)–4(c)) at lower doses of two components, indicating that danshen and tanshinone IIA sufficiently enhance the potential of Schwann cell proliferation for neuron regeneration.
Negative_regulation (inhibited) of PAI-1 in neuron
12) Confidence 0.14 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2997511 Disease Relevance 0 Pain Relevance 0
In contrast, PAI-1 is thought to be the major inhibitor of uPA [20].
Negative_regulation (inhibitor) of PAI-1
13) Confidence 0.14 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2997511 Disease Relevance 0.25 Pain Relevance 0.03
Thus, the coronary vasospasm induced the release of t-PA from endothelial cells of coronary vessels and resulted in the reduction in the PAI activity in the great cardiac vein.
Negative_regulation (reduction) of PAI in endothelial cells associated with coronary vasospasm
14) Confidence 0.13 Published 1990 Journal Jpn. Circ. J. Section Abstract Doc Link 2125083 Disease Relevance 0.70 Pain Relevance 0.19
The maximal dose of ergonovine (0.4 mg) induced mild diffuse coronary vasoconstriction in the controls, and this diffuse coronary vasoconstriction induced a reduction of PAI levels in the great cardiac vein from 11.9 +/- 4.9 IU/ml to 9.5 +/- 4.8 IU/ml (p less than 0.05).
Negative_regulation (reduction) of PAI in vein associated with increased venous pressure under development
15) Confidence 0.13 Published 1990 Journal Jpn. Circ. J. Section Abstract Doc Link 2125083 Disease Relevance 0.82 Pain Relevance 0.23
Combined determination of urokinase-type plasminogen activator (uPA) and its inhibitor, activator inhibitor type 1 (PAI-1), supports risk-adapted individualized therapy concepts, particularly in node-negative breast cancer.
Negative_regulation (determination) of PAI-1 in node associated with breast cancer
16) Confidence 0.12 Published 2004 Journal Clin. Breast Cancer Section Abstract Doc Link 15585071 Disease Relevance 0.69 Pain Relevance 0
In healthy women taking oral contraception, there is an increase of fibrinolytic proteins: elevation of plasmin, factors VII, X, IX and a decrease of plasminogen activator inhibitor (PAI) [12-14].
Negative_regulation (decrease) of activator inhibitor
17) Confidence 0.12 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2918592 Disease Relevance 0.30 Pain Relevance 0.20
Attempts to decrease insulin resistance such as fasting, diet, or administration of an oral anti-diabetic drug such as Metformin induced a parallel decrease in plasma insulin and plasminogen activator inhibitor 1 levels.
Negative_regulation (decrease) of activator inhibitor 1 in plasma associated with diabetes mellitus and insulin resistance
18) Confidence 0.10 Published 1991 Journal Diabetologia Section Abstract Doc Link 1916049 Disease Relevance 0.91 Pain Relevance 0.09
Serum levels of cholesterol, HDL-cholesterol, triglycerides, lipoprotein Lp(a), and the fibrinolysis factors tPA (tissue plasminogen activator) and PAI-1 activity (plasminogen activator inhibitor) were compared with sensory thresholds for vibration, electrical current perception, and pain in a population-based study comprising 239 patients with diabetes mellitus Type 1, aged 15-50 years.
Negative_regulation (inhibitor) of PAI-1 associated with pain, diabetes mellitus and disorder of lipid metabolism
19) Confidence 0.05 Published 1995 Journal Diabet. Med. Section Abstract Doc Link 7554780 Disease Relevance 0.58 Pain Relevance 0.10
In our study, PAI-1 was also significantly reduced in Hemin-treated animals, most at later time points.
Negative_regulation (reduced) of PAI-1
20) Confidence 0.05 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3001459 Disease Relevance 0.86 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox